Tuesday, July 8, 2025 7/8/2025

A2A ADENOSINE RECEPTOR AGONIST FOR THE TREATMENT OF IBD

Award Number: R43DK066880
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2004
PERIOD OF PERFORMANCE END DATE: 03/31/2008

Group Awards By:

View Award Description

A2A ADENOSINE RECEPTOR AGONIST FOR THE TREATMENT OF IBD - DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosine receptors. One of these compounds, ATL146e, is a coronary vasodilator and has been developed (with the aid of SBIR funding) as a coronary artery imaging agent that has been licensed to Bristol Meyers Squibb exclusively for pharmacological imaging of coronary disease and is currently in phase I clinical trials. ATL146e and other agonists of A2A adenosine receptors exert powerful anti-inflammatory effects by actions on bone-marrow derived cells at doses far below those that are vasoactive. Dr. Fabio Cominelli and his colleagues in the University of Virginia (UVa) are experts in the study of inflammatory bowel diseases (IBD). They have found in rabbit models that ATL146e is profoundly protective against inflammation and injury that occurs as a result of ulcerative colitis. This is an SBIR-AT phase I proposal by ATL and UVa for the purpose of developing ATL146e and a second generation orally active compound as new therapies for the treatment of IBD. This concept will be tested in a relevant mouse model of IBD that has been well characterized by the Cominelli laboratory. The aims are: (1) to optimize drug dosing and timing; (2) determine if ATL146e can delay the onset of disease symptoms; (3) characterize a second generation orally active compound; (4) synthesize new compounds and radioactive analogs; and (5) determine the chemical properties, pharmacokinetics and biodistribution of drug candidates. There is a great need for improved therapies for IBD. Our goal is to begin clinical trials with a new drug for the treatment of IBD within two years and to develop a second generation compound within four years.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $0 )
2010	2005	ADENOSINE THERAPEUTICS, LLC	PO BOX 4632	CHARLOTTESVILLE	VA	22905	CHARLOTTESVILLE CITY	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	11/11/2009	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2005 ( Subtotal = $335,663 )
2005	2005	ADENOSINE THERAPEUTICS, LLC	PO BOX 4632	CHARLOTTESVILLE	VA	22905	CHARLOTTESVILLE CITY	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	9/26/2005	NON-COMPETING CONTINUATION	$335,663
														Subtotal = $335,663

Issue Date FY: 2004 ( Subtotal = $337,360 )
2004	2004	ADENOSINE THERAPEUTICS, LLC	PO BOX 4632	CHARLOTTESVILLE	VA	22905	CHARLOTTESVILLE CITY	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	5/21/2004	NEW	$337,360
														Subtotal = $337,360

Grand Total All Awards = $673,023

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A2A ADENOSINE RECEPTOR AGONIST FOR THE TREATMENT OF IBD

Award Number: R43DK066880

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2004

PERIOD OF PERFORMANCE END DATE: 03/31/2008

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer